Newsmakers

Healthcare

CytoDyn (OTC: CYDY) Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to Enroll More Than 20 Patients in its 22 Solid Tumor Cancer Trial in the Next 60 Days

March 2, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to Enroll More Than 20 Patients in its 22 Solid Tumor Cancer Trial in the Next 60 Days

VANCOUVER, Washington, March 02, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]

Healthcare

CytoDyn to Hold Conference Call for Updates on Filing Phase 2 Trial with FDA for Treatment of Coronavirus in U.S., Status of BLA, Breakthrough Therapy Designation, Basket Trial for 22 Solid Tumor Cancers and Licensing Opportunities in Several Countries

February 28, 2020 admin Comments Off on CytoDyn to Hold Conference Call for Updates on Filing Phase 2 Trial with FDA for Treatment of Coronavirus in U.S., Status of BLA, Breakthrough Therapy Designation, Basket Trial for 22 Solid Tumor Cancers and Licensing Opportunities in Several Countries

VANCOUVER, Washington, Feb 28, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]

Newsmakers

NexTech (OTC: NEXCF)Lands Four New WebAR Customers

February 27, 2020 admin Comments Off on NexTech (OTC: NEXCF)Lands Four New WebAR Customers

New customer wins expected to scale rapidly with launch of NexTech’s CaptureAR technology NEW YORK and TORONTO, Feb. 27, 2020 — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for eCommerce and AR learning […]

Newsmakers

Imagination Park Technology (OTC: IPNFF) Announces Closing of Oversubscribed Convertible Debenture for $1,500,000

February 26, 2020 admin Comments Off on Imagination Park Technology (OTC: IPNFF) Announces Closing of Oversubscribed Convertible Debenture for $1,500,000

Vancouver, CANADA– February 26, 2020 – Imagination Park Technologies Inc. (CSE: IP) (OTC: IPNFF) is pleased to announce that it has closed its previously announced convertible debenture for an oversubscribed total amount of $1,500,000. The Company intends […]

Newsmakers

CytoDyn (OTC: CYDY) Receives Institutional Review Board Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers

February 21, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Receives Institutional Review Board Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers

VANCOUVER, Washington, Feb 21, 2020  — Results from mTNBC and MBC studies continues to be positive with the first patient now at almost five months of treatment showing zero CTC, EMT and CAML. Seven patients […]

Newsmakers

NexTech AR Solutions (OTC: NEXCF) to Webcast Live at VirtualInvestorConferences.com February 20th

February 18, 2020 admin Comments Off on NexTech AR Solutions (OTC: NEXCF) to Webcast Live at VirtualInvestorConferences.com February 20th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com NEW YORK, and TORONTO, Feb. 17, 2020  — NexTech AR Solutions (otcqb:NEXCF) (NTAR)(N29), based in Toronto Canada, today announced that […]

Healthcare

CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

February 14, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

VANCOUVER, Washington, Feb. 14, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]

Newsmakers

NexTech (OTC: NEXCF) Receives New 2020 Contract from Walther Arms Inc., Manufacturer of James Bond’s PPK

February 12, 2020 admin Comments Off on NexTech (OTC: NEXCF) Receives New 2020 Contract from Walther Arms Inc., Manufacturer of James Bond’s PPK

NEW YORK and TORONTO, Feb. 12, 2020  — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for e-commerce and AR learning applications, has received a new order from Walther Arms, most famous as the […]